Joseph Group Capital Management acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 150 shares of the medical research company’s stock, valued at approximately $34,000.
Several other hedge funds also recently made changes to their positions in AMGN. First Trust Advisors LP grew its stake in shares of Amgen by 125.5% in the fourth quarter. First Trust Advisors LP now owns 1,613,704 shares of the medical research company’s stock worth $363,035,000 after acquiring an additional 898,059 shares during the period. Two Sigma Advisers LP grew its stake in shares of Amgen by 44.7% in the third quarter. Two Sigma Advisers LP now owns 1,852,400 shares of the medical research company’s stock worth $393,913,000 after acquiring an additional 572,000 shares during the period. Franklin Resources Inc. grew its stake in shares of Amgen by 15.8% in the third quarter. Franklin Resources Inc. now owns 3,959,885 shares of the medical research company’s stock worth $842,069,000 after acquiring an additional 539,342 shares during the period. Capitolis Advisors LLC boosted its holdings in shares of Amgen by 532.9% in the third quarter. Capitolis Advisors LLC now owns 497,801 shares of the medical research company’s stock worth $101,118,000 after buying an additional 419,152 shares during the last quarter. Finally, Boston Partners boosted its holdings in shares of Amgen by 57.1% in the fourth quarter. Boston Partners now owns 1,135,035 shares of the medical research company’s stock worth $255,349,000 after buying an additional 412,337 shares during the last quarter. Hedge funds and other institutional investors own 79.01% of the company’s stock.
AMGN traded down $1.32 during trading hours on Friday, hitting $243.40. The company’s stock had a trading volume of 2,631,841 shares, compared to its average volume of 3,190,039. The business’s 50-day moving average price is $241.68 and its 200-day moving average price is $227.38. Amgen Inc. has a 12 month low of $198.64 and a 12 month high of $258.45. The stock has a market cap of $130.02 billion, a price-to-earnings ratio of 23.96, a P/E/G ratio of 1.67 and a beta of 0.58. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 8th. Shareholders of record on Tuesday, May 17th will be given a dividend of $1.94 per share. This represents a $7.76 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Monday, May 16th. Amgen’s dividend payout ratio (DPR) is 76.38%.
In other Amgen news, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total transaction of $3,264,435.00. Following the transaction, the executive vice president now owns 37,333 shares in the company, valued at $9,027,492.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.46% of the company’s stock.
A number of research firms recently issued reports on AMGN. Oppenheimer downgraded shares of Amgen to an “outperform” rating and set a $285.00 price objective on the stock. in a report on Tuesday, May 3rd. Barclays raised their price objective on shares of Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a report on Tuesday, April 12th. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 5th. Mizuho raised their price objective on shares of Amgen from $202.00 to $208.00 in a report on Tuesday. Finally, Jefferies Financial Group lifted their price target on shares of Amgen from $266.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, February 9th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $240.40.
Amgen Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.